Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA. Pelzer U, et al. Among authors: de jong fa. Br J Cancer. 2017 May 9;116(10):1247-1253. doi: 10.1038/bjc.2017.67. Epub 2017 Mar 28. Br J Cancer. 2017. PMID: 28350787 Free PMC article. Clinical Trial.
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, Patel DA, Ektare V, de Jong FA, Gill S. Vogel A, et al. Among authors: de jong fa. Cancer Treat Rev. 2016 Nov;50:142-147. doi: 10.1016/j.ctrv.2016.09.001. Epub 2016 Sep 9. Cancer Treat Rev. 2016. PMID: 27676174 Review.
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA. Chen LT, et al. Among authors: de jong fa. Eur J Cancer. 2018 Dec;105:71-78. doi: 10.1016/j.ejca.2018.09.010. Epub 2018 Nov 8. Eur J Cancer. 2018. PMID: 30414528 Free article. Clinical Trial.
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT. Hubner RA, et al. Among authors: de jong fa. Eur J Cancer. 2019 Jan;106:24-33. doi: 10.1016/j.ejca.2018.09.029. Epub 2018 Nov 17. Eur J Cancer. 2019. PMID: 30458340 Free article. Clinical Trial.
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Chen LT, Macarulla T, Blanc JF, Mirakhur B, de Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Chen LT, et al. Among authors: de jong fa. Pancreatology. 2021 Jan;21(1):192-199. doi: 10.1016/j.pan.2020.10.029. Epub 2020 Oct 10. Pancreatology. 2021. PMID: 33214082 Free article. Clinical Trial.
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Völkel D, Youssef A, de Jong FA, Tsimberidou AM. Mahalingam D, et al. Among authors: de jong fa. Br J Clin Pharmacol. 2020 Sep;86(9):1836-1848. doi: 10.1111/bcp.14289. Epub 2020 Apr 12. Br J Clin Pharmacol. 2020. PMID: 32207164 Free PMC article. Clinical Trial.
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
van der Bol JM, Mathijssen RH, Creemers GJ, Planting AS, Loos WJ, Wiemer EA, Friberg LE, Verweij J, Sparreboom A, de Jong FA. van der Bol JM, et al. Among authors: de jong fa. Clin Cancer Res. 2010 Jan 15;16(2):736-42. doi: 10.1158/1078-0432.CCR-09-1526. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068078 Clinical Trial.
Effects of methimazole on the elimination of irinotecan.
van der Bol JM, Visser TJ, Loos WJ, de Jong FA, Wiemer EA, van Aken MO, Planting AS, Schellens JH, Verweij J, Mathijssen RH. van der Bol JM, et al. Among authors: de jong fa. Cancer Chemother Pharmacol. 2011 Jan;67(1):231-6. doi: 10.1007/s00280-010-1414-x. Epub 2010 Aug 1. Cancer Chemother Pharmacol. 2011. PMID: 20680278 Free PMC article.
59 results